On May 18, 2020 ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, reported that the Phase 1 study of ALX148 in patients with relapsed/refractory Non-Hodgkin Lymphoma has been selected for an e-Poster presentation at the Virtual 25th Annual Congress of EHA (Free EHA Whitepaper), June 11 – 14, 2020 (Press release, ALX Oncology, MAY 18, 2020, View Source [SID1234558246]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Virtual 25th Congress of EHA (Free EHA Whitepaper) Presentation Information
Title: ALX148, a CD47 blocker, in combination with rituximab in patients with relapsed/refractory (R/R) Non-Hodgkin Lymphoma (NHL) (Abstract #EP1247).
Session Title: Aggressive Non-Hodgkin Lymphoma – Clinical
Date: Friday, June 12